Jian Jin

US Patent:

20130137679, May 30, 2013

Filed:

Jul 1, 2011

Appl. No.:

13/807347

Inventors:

Jian Jin - Chapel Hill NC, US
Bryan Roth - Durham NC, US
Stephen Frye - Chapel Hill NC, US

International Classification:

C07D 403/12
A61K 31/551
A61K 31/4725
C07D 417/12
C07D 405/14
A61K 31/55
A61K 31/538
A61K 31/4965
A61K 45/00
A61K 31/454
C07D 471/04
C07D 413/14
C07D 241/04
C07D 401/12
A61K 31/496
C07D 217/22
C07D 403/02

US Classification:

514218, 5142305, 51425304, 51425402, 51425406, 51425503, 514309, 514322, 540575, 544121, 544362, 544368, 544371, 544400, 546141, 546199

Abstract:

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, FIG. including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

US Patent:

20210355476, Nov 18, 2021

Filed:

Aug 3, 2018

Appl. No.:

16/636464

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Kyle Butler - Salt Lake City UT, US
Anna Chiarella - Chapel Hill NC, US

International Classification:

C12N 9/90
C12N 9/22
C12N 15/11
A61K 31/436
A61K 31/167
A61K 38/15
A61K 47/55
C07K 14/47

Abstract:

The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

US Patent:

20200181116, Jun 11, 2020

Filed:

Jun 29, 2018

Appl. No.:

16/622073

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Ian MacDonald - Durham NC, US
Kyle Butler - Salt Lake City UT, US

International Classification:

C07D 401/14
G01N 33/574
G01N 33/68
C07D 401/12
C07D 495/04

Abstract:

The present disclosure relates to chemical compounds that inhibit HP1-mediated heterochromatin formation, pharmaceutical compositions containing such compounds, methods of identifying such compounds, and their use in the treatment of disorders related to heterochromatin formation such as, for example, a disorder of cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20190330237, Oct 31, 2019

Filed:

Jul 20, 2017

Appl. No.:

16/318991

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Lindsey James - Chapel Hill NC, US
Sam Pellock - Chapel Hill NC, US
Ranathunga Arachchillage Yamu Ariyarathna - Carrboro NC, US
Stephen Frye - Chapel Hill NC, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C07D 513/14

Abstract:

Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.

US Patent:

20190201402, Jul 4, 2019

Filed:

May 17, 2017

Appl. No.:

16/301511

Inventors:

- Durham NC, US
- Chapel Hill NC, US
Hyeong-min Lee - Chapel Hill NC, US
Jian Jin - New York NY, US
Bryan L. Roth - Durham NC, US

International Classification:

A61K 31/517
A61P 43/00
A61K 31/551

Abstract:

The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.